Informations générales (source: ClinicalTrials.gov)
Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort (COCO-LATE)
Interventional
N/A
Tourcoing Hospital (Voir sur ClinicalTrials)
décembre 2020
août 2025
29 juin 2024
Several publications document the occurrence of symptoms that persist or occur late.
The identification of the observed clinical manifestations and their clinical and
paraclinical description are essential to better understand the natural evolution of
COVID-19, to clarify the pathophysiological mechanism of these possible late
manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study
focusing on symptomatic patients is needed.
Etablissements
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
CH SUD SEINE ET MARNE SITE MONTEREAU | Contact (sur clinicalTrials) | ||||
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
Centre Hospitalier Bretagne Atlantique - Vannes - France | Contact (sur clinicalTrials) | ||||
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
AP-HP Hôpital Hôtel-Dieu - Paris - France | Contact (sur clinicalTrials) | ||||
Ch Auxerre - Auxerre - France | Contact (sur clinicalTrials) | ||||
CH Melun Marc Jacquet - Melun - France | Contact (sur clinicalTrials) | ||||
CH Tourcoing - Tourcoing - France | Contact (sur clinicalTrials) | ||||
CHRU Lille - Lille - France | Contact (sur clinicalTrials) | ||||
CHRU Nancy - Vandœuvre-lès-Nancy - France | Contact (sur clinicalTrials) | ||||
CHRU Tours - Tours - France | Contact (sur clinicalTrials) | ||||
CHU Caen - Caen - France | Contact (sur clinicalTrials) | ||||
CHU de Saint-Etienne - Saint-Priest-en-Jarez - France | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
- History of symptomatic CoV-2-SARS infection as defined by :
o Positive RT-PCR SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
o Associated with at least one event : x Anosmia occurring after February 2020 x OR
COVID 19 evocative scanner x OR ≥ 2 contemporary symptoms of the virological sample
from: asthenia, cough, dyspnea, fever, myalgia, dysgeusia, diarrhea AND not present
prior to diagnosis
- AND persistence of at least one symptom present in the first 3 weeks of a COVID-19,
more than 8 weeks away from the first symptoms of COVID-19. OR late onset of at
least one new symptom a minimum of 3 weeks and a maximum of 6 months after the first
symptoms of a CoV-2 SARS infection.
- First symptoms less than 6 months old on the day of inclusion
- To benefit from a State Health Insurance or Medical Aid plan
- Have signed an informed consent for inclusion.
- History of symptomatic CoV-2-SARS infection as defined by :
o Positive RT-PCR SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
o Associated with at least one event : x Anosmia occurring after February 2020 x OR
COVID 19 evocative scanner x OR ≥ 2 contemporary symptoms of the virological sample
from: asthenia, cough, dyspnea, fever, myalgia, dysgeusia, diarrhea AND not present
prior to diagnosis
- AND persistence of at least one symptom present in the first 3 weeks of a COVID-19,
more than 8 weeks away from the first symptoms of COVID-19. OR late onset of at
least one new symptom a minimum of 3 weeks and a maximum of 6 months after the first
symptoms of a CoV-2 SARS infection.
- First symptoms less than 6 months old on the day of inclusion
- To benefit from a State Health Insurance or Medical Aid plan
- Have signed an informed consent for inclusion.
- Minor patient
- Patient under protection of justice
- Patient who required intensive care management :
- more than 5 days
- OR requiring orotracheal intubation
- OR having required high flow ventilation (optiflow)